ORIGINAL ARTICLE

Melanoma inhibitor of apoptosis protein is expressed differentially in melanoma and melanocytic naevus, but similarly in primary and metastatic melanomas

J Gong, N Chen, Q Zhou, B Yang, Y Wang and X Wang

Pathology Department, West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, China

Correspondence to:
Correspondence to:
Dr Q Zhou
Pathology Department, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China; zhouqiao{at}mcwcums.com

Background: Malignant melanoma is highly resistant to current treatments. The inhibitor of apoptosis protein (IAP) family member, melanoma IAP (ML-IAP), is overexpressed in some melanoma cell lines, rendering them resistant to apoptotic signals. Targeting ML-IAP is a promising approach to treating melanoma. However, the status of ML-IAP expression in human melanoma tissues and the difference in expression between melanoma and melanocytic naevus are not known.

Aims: To investigate these issues.

Methods: ML-IAP expression in 48 archived patient samples (34 melanomas and 14 dermal naevi) was assessed by immunohistochemistry and by in situ hybridisation and reverse transcription polymerase chain reaction (RT-PCR) assays developed for the study.

Results: Expression of ML-IAP was detected in 47.6–70.6% (10 of 21 to 24 of 34) of the melanomas, varying with detection methods. The expression rate in melanoma was much higher than that in melanocytic naevus (10.0–21.4%; one of 10 to three of 14). No significant difference was seen between primary and secondary melanomas. ML-IAP expression rates assessed by the three methods were in agreement.

Conclusions: The ML-IAP expression rate in archived melanoma tissues is around 50–70%, with no difference between primary and secondary melanomas. A small number of dermal naevi ( 20%) also expressed ML-IAP.

Abbreviations: BIR, baculoviral inhibitory repeat; DIG, digoxigenin; ML-IAP, melanoma inhibitor of apoptosis protein; RT-PCR, reverse transcription polymerase chain reaction; SMAC, second mitochondrial activator of caspases; SSC, saline sodium citrate

Keywords: inhibitor of apoptosis protein; ML-IAP; melanoma; naevus; expression

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Abd-Elrahman, I., Hershko, K., Neuman, T., Nachmias, B., Perlman, R., Ben-Yehuda, D. (2009). The Inhibitor of Apoptosis Protein Livin (ML-IAP) Plays a Dual Role in Tumorigenicity. Cancer Res. 69: 5475-5480 [Abstract] [Full Text]  
• Dynek, J. N., Chan, S. M., Liu, J., Zha, J., Fairbrother, W. J., Vucic, D. (2008). Microphthalmia-Associated Transcription Factor Is a Critical Transcriptional Regulator of Melanoma Inhibitor of Apoptosis in Melanomas. Cancer Res. 68: 3124-3132 [Abstract] [Full Text]  
• Vucic, D., Fairbrother, W. J. (2007). The Inhibitor of Apoptosis Proteins as Therapeutic Targets in Cancer. Clin. Cancer Res. 13: 5995-6000 [Abstract] [Full Text]